(BEAM) Beam Therapeutics - Ratings and Ratios
Base Editing Therapies
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 111% |
| Value at Risk 5%th | 156% |
| Relative Tail Risk | -14.56% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.72 |
| Alpha | -0.89 |
| CAGR/Max DD | -0.12 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.502 |
| Beta | 1.647 |
| Beta Downside | 1.802 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.20% |
| Mean DD | 45.69% |
| Median DD | 47.56% |
Description: BEAM Beam Therapeutics January 14, 2026
Beam Therapeutics Inc. (NASDAQ: BEAM) is a Cambridge-based biotech focused on precision genetic medicines using base-editing and CRISPR-derived platforms. Its pipeline centers on in-vivo liver-targeted LNP programs (BEAM-301 for glycogen storage disease 1a, BEAM-302 for severe alpha-1 antitrypsin deficiency) and a hematology program (BEAM-101 for sickle-cell disease), with additional early-stage assets such as the anti-CD117 antibody BEAM-103, a cell-therapy candidate BEAM-104, and ex-vivo CAR-T candidates (e.g., BEAM-201).
Strategic collaborations amplify its R&D reach: a multi-year agreement with Pfizer funds in-vivo base-editing projects for rare liver, muscle, and CNS disorders; a preclinical deal with Apellis targets complement-system genes; partnerships with Verve (cardiovascular), Sana (CRISPR Cas12b for cell therapy), and Orbital Therapeutics (RNA design). These alliances collectively provide non-dilutive capital and access to complementary expertise.
Key financial metrics (Q2 2024): cash and equivalents ≈ $620 million, giving a runway of roughly 18 months at current burn; market capitalization ≈ $2.3 billion; and a recent Phase 1/2 read-out for BEAM-101 showed a ≈ 50 % reduction in hemolysis biomarkers and a favorable safety profile, positioning the program for a Phase 2/3 launch decision in 2025. The broader gene-editing sector is benefiting from expanding FDA guidance on genome-editing therapies and increasing investor appetite for high-precision, potentially curative modalities.
Given the early-stage nature of most assets and the reliance on partnership funding, valuation hinges heavily on the timing and outcomes of BEAM-101 and the liver-targeted LNP programs; a delay or adverse safety signal would materially downgrade the upside.
For a deeper quantitative assessment, see the ValueRay analysis of BEAM.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-414.6m TTM) > 0 and > 6% of Revenue (6% = 3.34m TTM) |
| FCFTA -0.27 (>2.0%) and ΔFCFTA -14.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1644 % (prev 222.9%; Δ 1422 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.26 (>3.0%) and CFO -338.2m > Net Income -414.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (102.6m) change vs 12m ago 24.46% (target <= -2.0% for YES) |
| Gross Margin -639.3% (prev 7.13%; Δ -646.4pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 4.49% (prev 29.85%; Δ -25.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -19.47 (EBITDA TTM -430.1m / Interest Expense TTM 23.2m) >= 6 (WARN >= 3) |
Altman Z'' -8.32
| (A) 0.70 = (Total Current Assets 1.10b - Total Current Liabilities 182.6m) / Total Assets 1.31b |
| (B) -1.44 = Retained Earnings (Balance) -1.89b / Total Assets 1.31b |
| warn (B) unusual magnitude: -1.44 — check mapping/units |
| (C) -0.36 = EBIT TTM -452.2m / Avg Total Assets 1.24b |
| (D) -5.47 = Book Value of Equity -1.89b / Total Liabilities 345.1m |
| Total Rating: -8.32 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.10
| 1. Piotroski 0.0pt |
| 2. FCF Yield -18.82% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.16 |
| 5. Debt/Ebitda 0.27 |
| 6. ROIC - WACC (= -48.60)% |
| 7. RoE -42.86% |
| 8. Rev. Trend -32.24% |
| 9. EPS Trend 11.69% |
What is the price of BEAM shares?
Over the past week, the price has changed by +21.91%, over one month by +28.77%, over three months by +36.08% and over the past year by +35.28%.
Is BEAM a buy, sell or hold?
- Strong Buy: 10
- Buy: 4
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BEAM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.2 | 30.8% |
| Analysts Target Price | 45.2 | 30.8% |
| ValueRay Target Price | 36.6 | 5.8% |
BEAM Fundamental Data Overview January 11, 2026
P/B = 2.894
Beta = 2.073
Revenue TTM = 55.7m USD
EBIT TTM = -452.2m USD
EBITDA TTM = -430.1m USD
Long Term Debt = 151.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.7m USD (from shortTermDebt, last quarter)
Debt = 151.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -116.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.87b USD (2.80b + Debt 151.4m - CCE 1.07b)
Interest Coverage Ratio = -19.47 (Ebit TTM -452.2m / Interest Expense TTM 23.2m)
EV/FCF = -5.31x (Enterprise Value 1.87b / FCF TTM -352.4m)
FCF Yield = -18.82% (FCF TTM -352.4m / Enterprise Value 1.87b)
FCF Margin = -632.6% (FCF TTM -352.4m / Revenue TTM 55.7m)
Net Margin = -744.4% (Net Income TTM -414.6m / Revenue TTM 55.7m)
Gross Margin = -639.3% ((Revenue TTM 55.7m - Cost of Revenue TTM 411.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.43 (Enterprise Value 1.87b / Total Assets 1.31b)
Interest Expense / Debt = 7.20% (Interest Expense 10.9m / Debt 151.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -357.2m (EBIT -452.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.02 (Total Current Assets 1.10b / Total Current Liabilities 182.6m)
Debt / Equity = 0.16 (Debt 151.4m / totalStockholderEquity, last quarter 966.0m)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -116.5m / EBITDA -430.1m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -116.5m / FCF TTM -352.4m)
Total Stockholder Equity = 967.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.41% (Net Income -414.6m / Total Assets 1.31b)
RoE = -42.86% (Net Income TTM -414.6m / Total Stockholder Equity 967.4m)
RoCE = -40.42% (EBIT -452.2m / Capital Employed (Equity 967.4m + L.T.Debt 151.4m))
RoIC = -36.93% (negative operating profit) (NOPAT -357.2m / Invested Capital 967.4m)
WACC = 11.67% (E(2.80b)/V(2.95b) * Re(11.99%) + D(151.4m)/V(2.95b) * Rd(7.20%) * (1-Tc(0.21)))
Discount Rate = 11.99% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.23%
Fair Price DCF = unknown (Cash Flow -352.4m)
EPS Correlation: 11.69 | EPS CAGR: 28.07% | SUE: 1.20 | # QB: 1
Revenue Correlation: -32.24 | Revenue CAGR: -35.79% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.16 | Chg30d=-0.000 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-4.58 | Chg30d=-0.027 | Revisions Net=-8 | Growth EPS=-4.3% | Growth Revenue=+18.6%
Additional Sources for BEAM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle